Bayer claims early lead in Parkinson’s stem cell therapy
BlueRock unit's therapy was well tolerated Transplanted dopamine-making cells grow in brain Bayer to enrol patients for Phase II trial in H1 2024 By Ludwig Burger FRANKFURT, June 28 (Reuters)…